Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Dolby Laboratories Inc is an information technology services business based in the US. Dolby Laboratories shares (DLB) are listed on the NYSE and all prices are listed in US Dollars. Dolby Laboratories employs 2,289 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$91.35|
|52-week range||$69.44 - $104.26|
|50-day moving average||$91.37|
|200-day moving average||$96.81|
|Wall St. target price||$118.33|
|Dividend yield||$0.88 (0.95%)|
|Earnings per share (TTM)||$2.81|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||-0.79%|
|1 month (2021-09-27)||-0.40%|
|3 months (2021-07-27)||-4.05%|
|6 months (2021-04-27)||-10.00%|
|1 year (2020-10-26)||28.16%|
|2 years (2019-10-25)||42.94%|
|3 years (2018-10-26)||39.59%|
|5 years (2016-10-26)||83.14%|
Valuing Dolby Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Dolby Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Dolby Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 33x. In other words, Dolby Laboratories shares trade at around 33x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Dolby Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4752. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Dolby Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Dolby Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $428.8 million.
The EBITDA is a measure of a Dolby Laboratories's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.3 billion|
|Operating margin TTM||26.12%|
|Gross profit TTM||$1 billion|
|Return on assets TTM||6.85%|
|Return on equity TTM||11.87%|
|Market capitalisation||$9.3 billion|
TTM: trailing 12 months
There are currently 618,332 Dolby Laboratories shares held short by investors – that's known as Dolby Laboratories's "short interest". This figure is 1.2% up from 610,955 last month.
There are a few different ways that this level of interest in shorting Dolby Laboratories shares can be evaluated.
Dolby Laboratories's "short interest ratio" (SIR) is the quantity of Dolby Laboratories shares currently shorted divided by the average quantity of Dolby Laboratories shares traded daily (recently around 330658.82352941). Dolby Laboratories's SIR currently stands at 1.87. In other words for every 100,000 Dolby Laboratories shares traded daily on the market, roughly 1870 shares are currently held short.
However Dolby Laboratories's short interest can also be evaluated against the total number of Dolby Laboratories shares, or, against the total number of tradable Dolby Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Dolby Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Dolby Laboratories shares in existence, roughly 10 shares are currently held short) or 0.0096% of the tradable shares (for every 100,000 tradable Dolby Laboratories shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Dolby Laboratories.
Find out more about how you can short Dolby Laboratories stock.
Dividend payout ratio: 24.79% of net profits
Recently Dolby Laboratories has paid out, on average, around 24.79% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.96% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Dolby Laboratories shareholders could enjoy a 0.96% return on their shares, in the form of dividend payments. In Dolby Laboratories's case, that would currently equate to about $0.88 per share.
While Dolby Laboratories's payout ratio might seem low, this can signify that Dolby Laboratories is investing more in its future growth.
Dolby Laboratories's most recent dividend payout was on 18 August 2021. The latest dividend was paid out to all shareholders who bought their shares by 9 August 2021 (the "ex-dividend date").
Over the last 12 months, Dolby Laboratories's shares have ranged in value from as little as $69.4354 up to $104.2587. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Dolby Laboratories's is 1.0063. This would suggest that Dolby Laboratories's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Dolby Laboratories, Inc. creates audio and imaging technologies that transform entertainment and communications at the cinema, at home, at work, and on mobile devices. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for a range of media applications. ; AVC, a digital video codec with high bandwidth efficiency used in media devices; Dolby AC-4, an audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for cinema and a range of media devices. Its audio technologies also include Dolby Digital, a digital audio coding technology that provides multichannel sound to applications; Dolby Digital Plus, a digital audio coding technology that offers audio transmission for a range of media applications and devices; Dolby TrueHD, a digital audio coding technology providing encoding for media application; Dolby Vision, an imaging technology for cinema and media devices; Dolby Voice, an audio conferencing technology; and HEVC, a digital video codec with high bandwidth efficiency to support for media devices. In addition, the company designs and manufactures digital cinema servers, cinema processors, amplifiers, loudspeakers, hardware components, video conferencing solutions, and other products for the cinema, television, broadcast, communication, and entertainment industries. Further, it offers various services to support theatrical and television production for cinema exhibition, broadcast, and home entertainment.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.